Clinical Microbiology Reviews最新文献_第10页

Group B Streptococcal Neonatal Meningitis. B 群链球菌新生儿脑膜炎。

IF 19 1区医学

Clinical Microbiology Reviews Pub Date : 2022-04-20 Epub Date: 2022-02-16 DOI: 10.1128/cmr.00079-21

Teresa Tavares, Liliana Pinho, Elva Bonifácio Andrade

{"title":"Group B Streptococcal Neonatal Meningitis.","authors":"Teresa Tavares, Liliana Pinho, Elva Bonifácio Andrade","doi":"10.1128/cmr.00079-21","DOIUrl":"10.1128/cmr.00079-21","url":null,"abstract":"Neonatal bacterial meningitis is a devastating disease, associated with high mortality and neurological disability, in both developed and developing countries. Streptococcus agalactiae, commonly referred to as group B Streptococcus (GBS), remains the most common bacterial cause of meningitis among infants younger than 90 days. Maternal colonization with GBS in the gastrointestinal and/or genitourinary tracts is the primary risk factor for neonatal invasive disease. Despite prophylactic intrapartum antibiotic administration to colonized women and improved neonatal intensive care, the incidence and morbidity associated with GBS meningitis have not declined since the 1970s. Among meningitis survivors, a significant number suffer from complex neurological or neuropsychiatric sequelae, implying that the pathophysiology and pathogenic mechanisms leading to brain injury and devastating outcomes are not yet fully understood. It is imperative to develop new therapeutic and neuroprotective approaches aiming at protecting the developing brain. In this review, we provide updated clinical information regarding the understanding of neonatal GBS meningitis, including epidemiology, diagnosis, management, and human evidence of the disease's underlying mechanisms. Finally, we explore the experimental models used to study GBS meningitis and discuss their clinical and physiologic relevance to the complexities of human disease.","PeriodicalId":10378,"journal":{"name":"Clinical Microbiology Reviews","volume":null,"pages":null},"PeriodicalIF":19.0,"publicationDate":"2022-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8849199/pdf/cmr.00079-21.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9298677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Environmental, Microbiological, and Immunological Features of Bacterial Biofilms Associated with Implanted Medical Devices. 与植入医疗器械相关的细菌生物膜的环境、微生物学和免疫学特征。

IF 36.8 1区医学

Clinical Microbiology Reviews Pub Date : 2022-04-20 Epub Date: 2022-01-19 DOI: 10.1128/cmr.00221-20

Marina Caldara, Cristina Belgiovine, Eleonora Secchi, Roberto Rusconi

引用次数: 28

Clinical and Public Health Implications of Human T-Lymphotropic Virus Type 1 Infection. 人类 T 淋巴细胞病毒 1 型感染的临床和公共卫生影响。

IF 19 1区医学

Clinical Microbiology Reviews Pub Date : 2022-04-20 Epub Date: 2022-02-23 DOI: 10.1128/cmr.00078-21

Nicolas Legrand, Skye McGregor, Rowena Bull, Sahar Bajis, Braulio Mark Valencia, Amrita Ronnachit, Lloyd Einsiedel, Antoine Gessain, John Kaldor, Marianne Martinello

{"title":"Clinical and Public Health Implications of Human T-Lymphotropic Virus Type 1 Infection.","authors":"Nicolas Legrand, Skye McGregor, Rowena Bull, Sahar Bajis, Braulio Mark Valencia, Amrita Ronnachit, Lloyd Einsiedel, Antoine Gessain, John Kaldor, Marianne Martinello","doi":"10.1128/cmr.00078-21","DOIUrl":"10.1128/cmr.00078-21","url":null,"abstract":"Human T-lymphotropic virus type 1 (HTLV-1) is estimated to affect 5 to 10 million people globally and can cause severe and potentially fatal disease, including adult T-cell leukemia/lymphoma (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). The burden of HTLV-1 infection appears to be geographically concentrated, with high prevalence in discrete regions and populations. While most high-income countries have introduced HTLV-1 screening of blood donations, few other public health measures have been implemented to prevent infection or its consequences. Recent advocacy from concerned researchers, clinicians, and community members has emphasized the potential for improved prevention and management of HTLV-1 infection. Despite all that has been learned in the 4 decades following the discovery of HTLV-1, gaps in knowledge across clinical and public health aspects persist, impeding optimal control and prevention, as well as the development of policies and guidelines. Awareness of HTLV-1 among health care providers, communities, and affected individuals remains limited, even in countries of endemicity. This review provides a comprehensive overview on HTLV-1 epidemiology and on clinical and public health and highlights key areas for further research and collaboration to advance the health of people with and at risk of HTLV-1 infection.","PeriodicalId":10378,"journal":{"name":"Clinical Microbiology Reviews","volume":null,"pages":null},"PeriodicalIF":19.0,"publicationDate":"2022-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941934/pdf/cmr.00078-21.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10765088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Comprehensive Review on the Role of the Gut Microbiome in Human Neurological Disorders. 肠道微生物组在人类神经系统疾病中的作用综述。

IF 36.8 1区医学

Clinical Microbiology Reviews Pub Date : 2022-01-19 Epub Date: 2022-01-05 DOI: 10.1128/CMR.00338-20

Shokufeh Ghasemian Sorboni, Hanieh Shakeri Moghaddam, Reza Jafarzadeh-Esfehani, Saman Soleimanpour

{"title":"A Comprehensive Review on the Role of the Gut Microbiome in Human Neurological Disorders.","authors":"Shokufeh Ghasemian Sorboni, Hanieh Shakeri Moghaddam, Reza Jafarzadeh-Esfehani, Saman Soleimanpour","doi":"10.1128/CMR.00338-20","DOIUrl":"10.1128/CMR.00338-20","url":null,"abstract":"The human body is full of an extensive number of commensal microbes, consisting of bacteria, viruses, and fungi, collectively termed the human microbiome. The initial acquisition of microbiota occurs from both the external and maternal environments, and the vast majority of them colonize the gastrointestinal tract (GIT). These microbial communities play a central role in the maturation and development of the immune system, the central nervous system, and the GIT system and are also responsible for essential metabolic pathways. Various factors, including host genetic predisposition, environmental factors, lifestyle, diet, antibiotic or nonantibiotic drug use, etc., affect the composition of the gut microbiota. Recent publications have highlighted that an imbalance in the gut microflora, known as dysbiosis, is associated with the onset and progression of neurological disorders. Moreover, characterization of the microbiome-host cross talk pathways provides insight into novel therapeutic strategies. Novel preclinical and clinical research on interventions related to the gut microbiome for treating neurological conditions, including autism spectrum disorders, Parkinson's disease, schizophrenia, multiple sclerosis, Alzheimer's disease, epilepsy, and stroke, hold significant promise. This review aims to present a comprehensive overview of the potential involvement of the human gut microbiome in the pathogenesis of neurological disorders, with a particular emphasis on the potential of microbe-based therapies and/or diagnostic microbial biomarkers. This review also discusses the potential health benefits of the administration of probiotics, prebiotics, postbiotics, and synbiotics and fecal microbiota transplantation in neurological disorders.","PeriodicalId":10378,"journal":{"name":"Clinical Microbiology Reviews","volume":null,"pages":null},"PeriodicalIF":36.8,"publicationDate":"2022-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8729913/pdf/cmr.00338-20.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10476068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 91

Klebsiella oxytoca Complex: Update on Taxonomy, Antimicrobial Resistance, and Virulence. 氧化克雷伯菌复合体:分类、耐药性和毒力的最新进展。

IF 36.8 1区医学

Clinical Microbiology Reviews Pub Date : 2022-01-19 Epub Date: 2021-12-01 DOI: 10.1128/CMR.00006-21

Jing Yang, Haiyan Long, Ya Hu, Yu Feng, Alan McNally, Zhiyong Zong

{"title":"Klebsiella oxytoca Complex: Update on Taxonomy, Antimicrobial Resistance, and Virulence.","authors":"Jing Yang, Haiyan Long, Ya Hu, Yu Feng, Alan McNally, Zhiyong Zong","doi":"10.1128/CMR.00006-21","DOIUrl":"https://doi.org/10.1128/CMR.00006-21","url":null,"abstract":"Klebsiella oxytoca is actually a complex of nine species-Klebsiella grimontii, Klebsiella huaxiensis, Klebsiella michiganensis, K. oxytoca, Klebsiella pasteurii, Klebsiella spallanzanii, and three unnamed novel species. Phenotypic tests can assign isolates to the complex, but precise species identification requires genome-based analysis. The K. oxytoca complex is a human commensal but also an opportunistic pathogen causing various infections, such as antibiotic-associated hemorrhagic colitis (AAHC), urinary tract infection, and bacteremia, and has caused outbreaks. Production of the cytotoxins tilivalline and tilimycin lead to AAHC, while many virulence factors seen in Klebsiella pneumoniae, such as capsular polysaccharides and fimbriae, have been found in the complex; however, their association with pathogenicity remains unclear. Among the 5,724 K. oxytoca clinical isolates in the SENTRY surveillance system, the rates of nonsusceptibility to carbapenems, ceftriaxone, ciprofloxacin, colistin, and tigecycline were 1.8%, 12.5%, 7.1%, 0.8%, and 0.1%, respectively. Resistance to carbapenems is increasing alarmingly. In addition to the intrinsic blaOXY, many genes encoding β-lactamases with varying spectra of hydrolysis, including extended-spectrum β-lactamases, such as a few CTX-M variants and several TEM and SHV variants, have been found. blaKPC-2 is the most common carbapenemase gene found in the complex and is mainly seen on IncN or IncF plasmids. Due to the ability to acquire antimicrobial resistance and the carriage of multiple virulence genes, the K. oxytoca complex has the potential to become a major threat to human health.","PeriodicalId":10378,"journal":{"name":"Clinical Microbiology Reviews","volume":null,"pages":null},"PeriodicalIF":36.8,"publicationDate":"2022-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635272/pdf/cmr.00006-21.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39682269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 37

Bioengineering Strategies for Developing Vaccines against Respiratory Viral Diseases. 开发呼吸道病毒疾病疫苗的生物工程战略。

IF 36.8 1区医学

Clinical Microbiology Reviews Pub Date : 2022-01-19 Epub Date: 2021-11-17 DOI: 10.1128/CMR.00123-21

Shalini Iyer, Rajesh Yadav, Smriti Agarwal, Shashank Tripathi, Rachit Agarwal

{"title":"Bioengineering Strategies for Developing Vaccines against Respiratory Viral Diseases.","authors":"Shalini Iyer, Rajesh Yadav, Smriti Agarwal, Shashank Tripathi, Rachit Agarwal","doi":"10.1128/CMR.00123-21","DOIUrl":"10.1128/CMR.00123-21","url":null,"abstract":"Respiratory viral pathogens like influenza and coronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have caused outbreaks leading to millions of deaths. Vaccinations are, to date, the best and most economical way to control such outbreaks and have been highly successful for several pathogens. Currently used vaccines for respiratory viral pathogens are primarily live attenuated or inactivated and can risk reversion to virulence or confer inadequate immunity. The recent trend of using potent biomolecules like DNA, RNA, and protein antigenic components to synthesize vaccines for diseases has shown promising results. Still, it remains challenging to translate due to their high susceptibility to degradation during storage and after delivery. Advances in bioengineering technology for vaccine design have made it possible to control the physicochemical properties of the vaccines for rapid synthesis, heightened antigen presentation, safer formulations, and more robust immunogenicity. Bioengineering techniques and materials have been used to synthesize several potent vaccines, approved or in trials, against coronavirus disease 2019 (COVID-19) and are being explored for influenza, SARS, and Middle East respiratory syndrome (MERS) vaccines as well. Here, we review bioengineering strategies such as the use of polymeric particles, liposomes, and virus-like particles in vaccine development against influenza and coronaviruses and the feasibility of adopting these technologies for clinical use.","PeriodicalId":10378,"journal":{"name":"Clinical Microbiology Reviews","volume":null,"pages":null},"PeriodicalIF":36.8,"publicationDate":"2022-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597982/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39740955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pathogenesis of Respiratory Viral and Fungal Coinfections. 呼吸道病毒和真菌共感染的发病机制。

IF 36.8 1区医学

Clinical Microbiology Reviews Pub Date : 2022-01-19 DOI: 10.1128/CMR.00094-21

Fabián Salazar, Elaine Bignell, Gordon D Brown, Peter C Cook, Adilia Warris

{"title":"Pathogenesis of Respiratory Viral and Fungal Coinfections.","authors":"Fabián Salazar, Elaine Bignell, Gordon D Brown, Peter C Cook, Adilia Warris","doi":"10.1128/CMR.00094-21","DOIUrl":"https://doi.org/10.1128/CMR.00094-21","url":null,"abstract":"Individuals suffering from severe viral respiratory tract infections have recently emerged as \"at risk\" groups for developing invasive fungal infections. Influenza virus is one of the most common causes of acute lower respiratory tract infections worldwide. Fungal infections complicating influenza pneumonia are associated with increased disease severity and mortality, with invasive pulmonary aspergillosis being the most common manifestation. Strikingly, similar observations have been made during the current coronavirus disease 2019 (COVID-19) pandemic. The copathogenesis of respiratory viral and fungal coinfections is complex and involves a dynamic interplay between the host immune defenses and the virulence of the microbes involved that often results in failure to return to homeostasis. In this review, we discuss the main mechanisms underlying susceptibility to invasive fungal disease following respiratory viral infections. A comprehensive understanding of these interactions will aid the development of therapeutic modalities against newly identified targets to prevent and treat these emerging coinfections.","PeriodicalId":10378,"journal":{"name":"Clinical Microbiology Reviews","volume":null,"pages":null},"PeriodicalIF":36.8,"publicationDate":"2022-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597983/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10317849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 47

Erratum for Ramasamy and Subbian, "Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis". Ramasamy和Subbian的勘误，“COVID-19发病机制中细胞因子风暴和I型干扰素反应的关键决定因素”。

IF 36.8 1区医学

Clinical Microbiology Reviews Pub Date : 2021-12-15 Epub Date: 2021-07-14 DOI: 10.1128/CMR.00163-21

Santhamani Ramasamy, Selvakumar Subbian

引用次数: 7

Trained Immunity as a Preventive Measure for Surgical Site Infections. 训练免疫作为手术部位感染的预防措施。

IF 36.8 1区医学

Clinical Microbiology Reviews Pub Date : 2021-12-15 Epub Date: 2021-09-29 DOI: 10.1128/CMR.00049-21

Lieke Ter Steeg, Jorge Domínguez-Andrés, Mihai G Netea, Leo A B Joosten, Reinout van Crevel

{"title":"Trained Immunity as a Preventive Measure for Surgical Site Infections.","authors":"Lieke Ter Steeg, Jorge Domínguez-Andrés, Mihai G Netea, Leo A B Joosten, Reinout van Crevel","doi":"10.1128/CMR.00049-21","DOIUrl":"https://doi.org/10.1128/CMR.00049-21","url":null,"abstract":"Even with strict implementation of preventive measures, surgical site infections (SSIs) remain among the most prevalent health care-associated infections. New strategies to prevent SSIs would thus have a huge impact, also in light of increasing global rates of antimicrobial drug resistance. Considering the indispensable role of innate immune cells in host defense in surgical wounds, enhancing their function may represent a potential strategy for prevention of SSIs. Trained immunity is characterized by metabolic, epigenetic, and functional reprogramming of innate immune cells. These functional changes take place at multiple levels, namely, at the level of bone marrow precursors, circulating innate immune cells, and resident tissue macrophages. Experimental studies have shown that induction of trained immunity can protect against various infections. Increasing evidence suggests that it may also lower the risk and severity of SSIs. This may occur through several different mechanisms. First, trained immunity enhances local host defense against soft tissue infections, including those caused by Staphylococcus aureus, the most common cause of SSIs. Second, training effects on nonimmune cells such as fibroblasts have been shown to improve wound repair. Third, trained immunity may prevent or reverse the postoperative immunoparalysis that contributes to risk of infections following surgery. There are multiple approaches to inducing trained immunity, such as vaccination with the bacillus Calmette-Guérin (BCG) tuberculosis vaccine, topical administration of β-glucan, or treatment with the Toll-like receptor 7 agonist imiquimod. Clinical-experimental studies should establish if and how induction of trained immunity can best help prevent SSIs and what patient groups would most benefit.","PeriodicalId":10378,"journal":{"name":"Clinical Microbiology Reviews","volume":null,"pages":null},"PeriodicalIF":36.8,"publicationDate":"2021-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510541/pdf/cmr.00049-21.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39467687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Natural-Product-Based Solutions for Tropical Infectious Diseases. 基于天然产品的热带传染病解决方案。

IF 19 1区医学

Clinical Microbiology Reviews Pub Date : 2021-12-15 Epub Date: 2021-09-08 DOI: 10.1128/CMR.00348-20

Oyelola Adegboye, Matt A Field, Andreas Kupz, Saparna Pai, Dileep Sharma, Michael J Smout, Phurpa Wangchuk, Yide Wong, Claire Loiseau

{"title":"Natural-Product-Based Solutions for Tropical Infectious Diseases.","authors":"Oyelola Adegboye, Matt A Field, Andreas Kupz, Saparna Pai, Dileep Sharma, Michael J Smout, Phurpa Wangchuk, Yide Wong, Claire Loiseau","doi":"10.1128/CMR.00348-20","DOIUrl":"10.1128/CMR.00348-20","url":null,"abstract":"About half of the world's population and 80% of the world's biodiversity can be found in the tropics. Many diseases are specific to the tropics, with at least 41 diseases caused by endemic bacteria, viruses, parasites, and fungi. Such diseases are of increasing concern, as the geographic range of tropical diseases is expanding due to climate change, urbanization, change in agricultural practices, deforestation, and loss of biodiversity. While traditional medicines have been used for centuries in the treatment of tropical diseases, the active natural compounds within these medicines remain largely unknown. In this review, we describe infectious diseases specific to the tropics, including their causative pathogens, modes of transmission, recent major outbreaks, and geographic locations. We further review current treatments for these tropical diseases, carefully consider the biodiscovery potential of the tropical biome, and discuss a range of technologies being used for drug development from natural resources. We provide a list of natural products with antimicrobial activity, detailing the source organisms and their effectiveness as treatment. We discuss how technological advancements, such as next-generation sequencing, are driving high-throughput natural product screening pipelines to identify compounds with therapeutic properties. This review demonstrates the impact natural products from the vast tropical biome have in the treatment of tropical infectious diseases and how high-throughput technical capacity will accelerate this discovery process.","PeriodicalId":10378,"journal":{"name":"Clinical Microbiology Reviews","volume":null,"pages":null},"PeriodicalIF":19.0,"publicationDate":"2021-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673330/pdf/cmr.00348-20.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39394332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0